A Phase 2, 12-Week, Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate Efficacy and Safety of GX-G6 on Glycaemic Control Versus Placebo and Open-Label Dulaglutide in Patients With Uncontrolled Type 2 Diabetes Mellitus
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 27 May 2019
Price : $35 *
At a glance
- Drugs GX G6 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Genexine
- 22 May 2019 Status changed from planning to not yet recruiting.
- 21 Aug 2018 New trial record
- 09 Aug 2018 According to I-MAB Biopharma media release, the company has received clinical trial approval from China National Drug Administration (CNDA).